Hetero’s Post

🌟 Exciting News! 🌟 The Medicines Patent Pool (MPP), the Access to Oncology Medicines Coalition (ATOM Coalition), IDA Foundation, and The Max Foundation (Max) are thrilled to announce that MPP sublicensee Hetero has received FDA approval for its generic version of #nilotinib, a treatment for chronic myeloid leukaemia. This marks a significant milestone in increasing access to cancer treatments in low- and middle-income countries. 🎙️ Charles Gore, Executive Director of MPP, highlights this achievement as a landmark in enhancing access to life-saving treatments for non-communicable diseases. 🎙️ Dan Milner, Executive Director of the Union for International Cancer Control (UICC)-led ATOM Coalition, emphasises the critical advancement in broadening access to #oncology drugs in underserved regions. 🎙️ Harm Veerkamp, NCDconnect Director, expresses excitement over this milestone, bringing hope to those affected by CML. 🎙️ Pat Garcia-Gonzalez, CEO of The Max Foundation, underscores the commitment to expanding access to quality drugs in LMICs. 🎙️ Dr. Vamsi Krishna Bandi, MD & CEO of Hetero, proudly states their dedication to expanding access to vital cancer treatments with their advanced manufacturing facilities. This development is crucial, considering the increasing #cancer cases and mortality in LMICs. Nilotinib, part of the World Health Organization Model List of Essential Medicines, offers an affordable treatment option for CML patients. Together, we are making a tangible difference for #cancer patients worldwide! 🌍💊 📃 Access the joint statement: https://bit.ly/3ZA1pBj #CancerTreatment #GlobalHealth #FDAApproval #MPP #ATOMCoalition #CML #ChronicMyeloidLeukaemia Unitaid, Swiss Agency for Development and Cooperation, Ministère des Affaires étrangères français, Ministry of Foreign Affairs of Japan, World Intellectual Property Organization – WIPO, Government of Canada